Image_1_Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.tiff
Background: 2,4,5-Trimethoxyamphetamine (TMA-2) is a potent psychedelic compound. Structurally related 4-alkyloxy-substituted 2,5-dimethoxyamphetamines and phenethylamine congeners (2C-O derivatives) have been described but their pharmacology is mostly undefined. Therefore, we examined receptor binding and activation profiles of these derivatives at monoamine receptors and transporters.
Methods: Receptor binding affinities were determined at the serotonergic 5-HT1A, 5-HT2A, and 5-HT2C receptors, trace amine-associated receptor 1 (TAAR1), adrenergic α1 and α2 receptors, dopaminergic D2 receptor, and at monoamine transporters, using target-transfected cells. Additionally, activation of 5-HT2A and 5-HT2B receptors and TAAR1 was determined. Furthermore, we assessed monoamine transporter inhibition.
Results: Both the phenethylamine and amphetamine derivatives (Ki = 8–1700 nM and 61–4400 nM, respectively) bound with moderate to high affinities to the 5-HT2A receptor with preference over the 5-HT1A and 5-HT2C receptors (5-HT2A/5-HT1A = 1.4–333 and 5-HT2A/5-HT2C = 2.1–14, respectively). Extending the 4-alkoxy-group generally increased binding affinities at 5-HT2A and 5-HT2C receptors but showed mixed effects in terms of activation potency and efficacy at these receptors. Introduction of a terminal fluorine atom into the 4-ethoxy substituent by trend decreased, and with progressive fluorination increased affinities at the 5-HT2A and 5-HT2C receptors. Little or no effect was observed at the 5-HT1A receptor for any of the substances tested (Ki ≥ 2700 nM). Phenethylamines bound more strongly to the TAAR1 (Ki = 21–3300 nM) compared with their amphetamine analogs (Ki = 630–3100 nM).
Conclusion: As seen with earlier series investigated, the 4-alkyloxy-substituted 2,5-dimethoxyamphetamines and phenethylamines share some trends with the many other phenethylamine pharmacophore containing compounds, such as when increasing the size of the 4-substituent and increasing the lipophilicity, the affinities at the 5-HT2A/C subtype also increase, and only weak 5-HT2A/C subtype selectivities were achieved. At least from the binding data available (i.e., high affinity binding at the 5-HT2A receptor) one may predict mainly psychedelic-like effects in humans, at least for some of the compound investigated herein.
History
References
- https://doi.org//10.1021/jm00256a016
- https://doi.org//10.1021/jm00236a023
- https://doi.org//10.1016/0028-3908(94)90059-0
- https://doi.org//10.1021/jm000491y
- https://doi.org//10.1016/S0960-894X(02)00306-2
- https://doi.org//10.1021/jm00327a016
- https://doi.org//10.1523/JNEUROSCI.5723-07.2008
- https://doi.org//10.1021/jm00144a009
- https://doi.org//10.1021/jm9906062
- https://doi.org//10.1021/jm00039a004
- https://doi.org//10.1016/0006-2952(83)90281-2
- https://doi.org//10.1021/jm00152a005
- https://doi.org//10.1177/0269881119826610
- https://doi.org//10.1021/jm00082a014
- https://doi.org//10.1016/0091-3057(82)90330-6
- https://doi.org//10.1021/jm00177a017
- https://doi.org//10.1037/e495832006-006
- https://doi.org//10.1016/j.neuropharm.2011.01.017
- https://doi.org//10.1016/0091-3057(90)90228-A
- https://doi.org//10.3389/fphar.2017.00814
- https://doi.org//10.1124/jpet.102.042184
- https://doi.org//10.1016/j.bmc.2008.06.009
- https://doi.org//10.1093/ijnp/pyy047
- https://doi.org//10.1016/j.neuropharm.2017.07.012
- https://doi.org//10.1016/j.ejphar.2019.05.014
- https://doi.org//10.1021/jm960199j
- https://doi.org//10.1124/jpet.106.117507
- https://doi.org//10.1007/PL00005315
- https://doi.org//10.1016/j.pharmthera.2003.11.002
- https://doi.org//10.3389/fphar.2018.00206
- https://doi.org//10.1021/cn500292d
- https://doi.org//10.1021/jm00051a011
- https://doi.org//10.1016/0024-3205(77)90099-6
- https://doi.org//10.1124/pr.115.011478
- https://doi.org//10.1021/jm00051a011
- https://doi.org//10.1111/j.1471-4159.2005.03477.x
- https://doi.org//10.1007/BF00443425
- https://doi.org//10.1016/j.cub.2016.12.030
- https://doi.org//10.1016/j.ejphar.2019.172515
- https://doi.org//10.1016/j.euroneuro.2016.05.001
- https://doi.org//10.1161/01.CIR.102.23.2836
- https://doi.org//10.1016/j.neuropharm.2015.08.034
- https://doi.org//10.1161/01.cir.102.23.2836
- https://doi.org//10.1021/jm00321a058
- https://doi.org//10.1124/jpet.115.229765
- https://doi.org//10.1007/BF01524590
- https://doi.org//10.1111/j.1476-5381.2012.02145.x
- https://doi.org//10.1002/hlca.200390224
- https://doi.org//10.1097/00001756-199812010-00024
- https://doi.org//10.1002/dta.413
- https://doi.org//10.1002/dta.413
- https://doi.org//10.1016/S0968-0896(02)00209-2
- https://doi.org//10.1016/s0968-0896(02)00209-2